✦ LIBER ✦

Phase 1, open-label, dose-escalation, and pharmacokinetic study of STAT3 inhibitor OPB-31121 in subjects with advanced solid tumors

✍ Scribed by Bendell, Johanna C.; Hong, David S.; Burris, Howard A.; Naing, Aung; Jones, Suzanne F.; Falchook, Gerald; Bricmont, Patricia; Elekes, Agnes; Rock, Edwin P.; Kurzrock, Razelle

Book ID: 125344317
Publisher: Springer
Year: 2014
Tongue: English
Weight: 189 KB
Volume: 74
Category: Article
ISSN: 0344-5704
DOI: 10.1007/s00280-014-2480-2

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase I Dose-Escalation and Pharmacokine

Phase I Dose-Escalation and Pharmacokinetic Study of Dasatinib in Patients with Advanced Solid Tumors

✍ Demetri, G. D.; Lo Russo, P.; MacPherson, I. R.J.; Wang, D.; Morgan, J. A.; Brun 📂 Article 📅 2009 🏛 American Association for Cancer Research 🌐 English ⚖ 238 KB

A Phase I, open-label, dose escalation s

A Phase I, open-label, dose escalation study of afatinib, in a 3-week-on/1-week-off schedule in patients with advanced solid tumors

✍ John Marshall,Jimmy Hwang,Ferry A. L. M. Eskens… 📂 Article 📅 2012 🏛 Springer US 🌐 English ⚖ 223 KB

A phase I dose-escalation and pharmacoki

A phase I dose-escalation and pharmacokinetic study of enzastaurin and erlotinib in patients with advanced solid tumors

✍ Sukhmani K. Padda; Yelena Krupitskaya; Laveena Chhatwani; George A. Fisher; Alex 📂 Article 📅 2011 🏛 Springer 🌐 English ⚖ 281 KB

A phase 1, open-label, dose-escalation s

A phase 1, open-label, dose-escalation study of BIIB022 (anti-IGF-1R monoclonal antibody) in subjects with relapsed or refractory solid tumors

✍ von Mehren, Margaret; Britten, Carolyn D.; Pieslor, Peter; Saville, Wayne; Vasso 📂 Article 📅 2014 🏛 Springer US 🌐 English ⚖ 229 KB

A Phase I, open-label, dose-escalation s

A Phase I, open-label, dose-escalation study of continuous once-daily oral treatment with afatinib in patients with advanced solid tumors

✍ Michael S. Gordon,David S. Mendelson,Mitchell Gross… 📂 Article 📅 2012 🏛 Springer US 🌐 English ⚖ 200 KB

Phase I, open-label, multicentre, dose-e

Phase I, open-label, multicentre, dose-escalation, pharmacokinetic and pharmacodynamic trial of the oral aurora kinase inhibitor PF-03814735 in advanced solid tumours

✍ Patrick Schöffski; Suzanne F. Jones; Herlinde Dumez; Jeffrey R. Infante; Elke Va 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 215 KB